JP7824222B2 - 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 - Google Patents
中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体Info
- Publication number
- JP7824222B2 JP7824222B2 JP2022548039A JP2022548039A JP7824222B2 JP 7824222 B2 JP7824222 B2 JP 7824222B2 JP 2022548039 A JP2022548039 A JP 2022548039A JP 2022548039 A JP2022548039 A JP 2022548039A JP 7824222 B2 JP7824222 B2 JP 7824222B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally replaced
- atoms
- compounds
- available
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279101A JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969894P | 2020-02-04 | 2020-02-04 | |
| US62/969,894 | 2020-02-04 | ||
| PCT/CA2021/050122 WO2021155467A1 (en) | 2020-02-04 | 2021-02-04 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Division JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023512821A JP2023512821A (ja) | 2023-03-29 |
| JP2023512821A5 JP2023512821A5 (https=) | 2024-02-13 |
| JPWO2021155467A5 JPWO2021155467A5 (https=) | 2024-02-13 |
| JP7824222B2 true JP7824222B2 (ja) | 2026-03-04 |
Family
ID=77199114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548039A Active JP7824222B2 (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11453689B2 (https=) |
| EP (1) | EP4100403A4 (https=) |
| JP (2) | JP7824222B2 (https=) |
| KR (1) | KR20220137085A (https=) |
| CN (1) | CN115380028A (https=) |
| AU (1) | AU2021215709A1 (https=) |
| BR (1) | BR112022015379A2 (https=) |
| CA (1) | CA3166940A1 (https=) |
| IL (1) | IL295374A (https=) |
| MX (1) | MX2022009528A (https=) |
| WO (1) | WO2021155467A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| JP2024520017A (ja) * | 2021-05-26 | 2024-05-21 | マインドセット ファーマ インコーポレイテッド | 幻覚剤と脂肪酸との併用 |
| EP4347559A4 (en) * | 2021-06-02 | 2025-04-09 | Saint Joseph's University | FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| AU2023215456A1 (en) * | 2022-02-01 | 2024-08-01 | Caamtech, Inc. | Psychedelic compounds and their therapeutic uses |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| KR20250034020A (ko) * | 2022-04-19 | 2025-03-10 | 마인드셋 파마 인크. | 세로토닌 관련 장애를 치료하는 데 유용한 세로토닌성 제제로서의 인돌린 유도체 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005062985A2 (en) | 2003-12-23 | 2005-07-14 | American Bioscience, Inc. | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| JP2018529680A (ja) | 2015-09-10 | 2018-10-11 | スヴェン・ライフ・サイエンシズ・リミテッド | ムスカリンｍ１受容体ポジティブアロステリックモジュレーターとしてのフルオロインドール誘導体 |
| WO2019067696A1 (en) | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| TW288010B (https=) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| SK280193B6 (sk) * | 1992-04-07 | 1999-09-10 | Pfizer Inc. | Indolové deriváty predstavujúce 5-ht1 agonisty, fa |
| ATE144773T1 (de) * | 1993-04-22 | 1996-11-15 | Pfizer Res & Dev | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| US5955462A (en) | 1996-10-31 | 1999-09-21 | Harbor Branch Oceanographic Institution, Inc. | Anti-neurogenic inflammatory compounds and compositions and methods of use thereof |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| WO2001094310A1 (en) | 2000-06-07 | 2001-12-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| ATE474833T1 (de) | 2004-09-22 | 2010-08-15 | Janssen Pharmaceutica Nv | Inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| ES2357129T3 (es) | 2005-04-13 | 2011-04-19 | Neuraxon Inc. | Compuestos indólicos sustituidos que tienen actividad inhibidora de nos. |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
| US20090306137A1 (en) * | 2006-05-22 | 2009-12-10 | Wolfgang Curt D | Treatment for depressive disorders |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| US20090014868A1 (en) | 2007-07-10 | 2009-01-15 | International Business Machines Corporation | Manufacturing ic chip in portions for later combining, and related structure |
| KR20100103799A (ko) | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| WO2010132072A1 (en) | 2009-05-15 | 2010-11-18 | Neuraxon, Inc | Treatment or prevention of migraine by dosing at aura |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| PT3160464T (pt) * | 2014-06-26 | 2018-10-12 | Contera Pharma Aps | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20190358238A1 (en) | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| AU2020215150B8 (en) | 2019-01-30 | 2025-07-03 | Diamond Therapeutics Inc. | Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| JP2023514559A (ja) | 2020-02-05 | 2023-04-06 | イエール ユニバーシティ | 頭痛障害の幻覚剤処置 |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| CN115867533B (zh) | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| WO2022018709A1 (en) | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions and methods for treatment of psychoses and psychotic disorders |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-02-04 MX MX2022009528A patent/MX2022009528A/es unknown
- 2021-02-04 EP EP21751045.2A patent/EP4100403A4/en active Pending
- 2021-02-04 KR KR1020227030622A patent/KR20220137085A/ko active Pending
- 2021-02-04 AU AU2021215709A patent/AU2021215709A1/en active Pending
- 2021-02-04 JP JP2022548039A patent/JP7824222B2/ja active Active
- 2021-02-04 IL IL295374A patent/IL295374A/en unknown
- 2021-02-04 CN CN202180026721.8A patent/CN115380028A/zh active Pending
- 2021-02-04 CA CA3166940A patent/CA3166940A1/en active Pending
- 2021-02-04 WO PCT/CA2021/050122 patent/WO2021155467A1/en not_active Ceased
- 2021-02-04 BR BR112022015379A patent/BR112022015379A2/pt unknown
- 2021-07-28 US US17/387,864 patent/US11453689B2/en active Active
-
2022
- 2022-08-02 US US17/879,320 patent/US12054504B2/en active Active
-
2024
- 2024-06-19 US US18/747,540 patent/US20240336641A1/en active Pending
-
2025
- 2025-12-23 JP JP2025279101A patent/JP2026053548A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005062985A2 (en) | 2003-12-23 | 2005-07-14 | American Bioscience, Inc. | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| JP2018529680A (ja) | 2015-09-10 | 2018-10-11 | スヴェン・ライフ・サイエンシズ・リミテッド | ムスカリンｍ１受容体ポジティブアロステリックモジュレーターとしてのフルオロインドール誘導体 |
| WO2019067696A1 (en) | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
Non-Patent Citations (5)
| Title |
|---|
| J. Pharm. Sci.，1975年，64，367-391 |
| Madina Gerasimov et al.，Further Studies on Oxygenated Tryptamines with LSD-like Activity Incorporating a Chiral Pyrrolidine Moiety into the Side Chain，J. Med. Chem.，1999年，42，4257-4263，DOI: 10.1021/jm990325u |
| REGISTRY（STN）[online]，CAS登録番号2116242-42-1 ほか１１件 |
| 佐藤 健太郎，化学よもやま話 重水素，ＴＣＩメール，2013年，2-5ページ |
| 製剤学・物理薬剤学，2012年，259-266 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3166940A1 (en) | 2021-08-12 |
| KR20220137085A (ko) | 2022-10-11 |
| EP4100403A1 (en) | 2022-12-14 |
| US20230105399A1 (en) | 2023-04-06 |
| US20240336641A1 (en) | 2024-10-10 |
| JP2026053548A (ja) | 2026-03-25 |
| MX2022009528A (es) | 2022-11-14 |
| US11453689B2 (en) | 2022-09-27 |
| US20220017550A1 (en) | 2022-01-20 |
| BR112022015379A2 (pt) | 2022-09-27 |
| JP2023512821A (ja) | 2023-03-29 |
| WO2021155467A1 (en) | 2021-08-12 |
| IL295374A (en) | 2022-10-01 |
| US12054504B2 (en) | 2024-08-06 |
| EP4100403A4 (en) | 2024-01-03 |
| AU2021215709A1 (en) | 2022-09-01 |
| CN115380028A (zh) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7824222B2 (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体 | |
| JP2026010068A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| US20240166630A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| AU2021394129A1 (en) | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders | |
| US20250034106A1 (en) | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto | |
| JP2025529948A (ja) | セロトニンに関する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 | |
| HK40083776A (en) | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| HK40105243A (zh) | 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物 | |
| HK40106138A (zh) | 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物 | |
| HK40091505A (zh) | 用於治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 | |
| HK40083780A (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A525 Effective date: 20221004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240202 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250410 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250710 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7824222 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |